Floatz logo

Mirogabalin

Fibromyalgia

Daiichi SankyoSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Fibromyalgia cohort.

Asset / SponsorPhaseRating
Duloxetine
Cukurova University
Phase 4BBB
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4BB
PIPERAZINE, 1-(BIS(4-FLUOROPHENYL)METHYL)-4-(3-PHENYL-2-PROPENYL)-, (E)-
Taipei Veterans General Hospital, Taiwan
Phase 4BB
Lidocaine
Peking University Third Hospital
Phase 2BB
Zonisamide
University of Pittsburgh
Phase 4B

View all 33 →

Same molecule, other indications

Mirogabalin is also rated in:

diabetic neuropathyActive
BBB
Indicative · Phase 4
79 / 100
View asset →
postherpetic neuralgiaDormant
BB
Indicative · Phase 3
64 / 100
View asset →
chemotherapy-induced neuropathyActive
NR
Indicative · N/A
/ 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →